SEC EDGARSEP 171 min read$ADPT

BOBULSKY SUSAN sold $32K of ADPT

BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 1,195 shares of Adaptive Biotechnologies Corp (ADPT) at $27.00 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · BOBULSKY SUSAN

Published Sep 17, 2026, 10:50 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 17, 2026, 10:53 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ADPT

Neutral

high confidence

Mentioned

$ADPT

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ADPTNeutralLow

Why it matters

The sale is modest and pre‑arranged, suggesting no immediate market impact.

Market read

Routine insider sale with limited trading relevance.

What to watch

Potential upcoming regulatory or clinical trial news not disclosed in the filing.

Relevance 2/10Novelty 3/10Timing: filed Sep 17 2026 (post‑market)

Background

Form 4 filing reports insider transactions required by SEC; provides transparency on officer holdings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ADPTNeutralHigh confidence

Context

Chief Commercial Officer sold 1,195 shares for $32,265 via a 10b5-1 plan on Sep 15, 2026

Expected impact

minimal impact; price likely unchanged

Evidence & confidence

The transaction amount is small relative to total holdings and market cap; such sales are routine and rarely affect price.

Market effects

Sector

None; insider sale does not affect biotech sector outlook.

Regional

None; limited to Adaptive Biotechnologies shareholders.

Global

None; isolated event.

Counterpoint

What could challenge this read

If the insider is reducing exposure, it could signal concerns about near‑term prospects.

Key entities

Company
Adaptive Biotechnologies Corp
US‑listed biotech firm (ticker ADPT).
Insider
Susan Bobulsky
Chief Commercial Officer, MRD at Adaptive Biotechnologies.

Read at source ← All news

SEP 29

$ADPTMed

ADPT Initiates Coverage On Goldman Sachs -- Rating Set to Buy

Goldman Sachs initiated coverage on Adaptive Biotechnologies (ADPT) with a Buy rating and a $35 price target, citing growth potential. The company's market cap is $4.55B. GuruFocus values ADPT at $11.61, suggesting it's 145.6% overvalued, with a GF Score of 72/100. Insider activity shows mixed sentiment.

gurufocus.com2 min

SEP 25

$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min

SEP 22

$ADPTMed

BTIG maintains Buy rating on Adaptive Biotechnologies, $34 price target

BTIG kept a Buy rating on Adaptive Biotechnologies with a $34 price target, suggesting a 22% upside from the Sep 21 close. The firm cited strong revenue growth, including a 22% YoY increase to $72M in Q2'26, and NCCN guideline updates supporting clonoSEQ for multiple myeloma assessments.

tradingview.com1 min

SEP 21

$ADPTHigh

BTIG raises Adeptus Biotechnologies price target to $34 on guidelines

BTIG raised its price target for Adeptus Biotechnologies (ADPT) to $34 from $25, citing updated cancer guidelines that feature its clonoSEQ assay. The stock has gained 109% over the past year. Adaptive Biotechnologies reported Q2 revenue of $71.6M, up 22% YoY, but missed earnings estimates. Guggenheim and BTIG also raised their price targets for Adaptive Biotechnologies.

investing.com2 min

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

AUG 20

$ADPTMed

ROBINS CHAD M sold $14.9M of ADPT

ROBINS CHAD M (CEO and Chairman) sold 600,000 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.80 ($24.48–$25.57, $14.88M total) across 4 trades over 2026-08-17 to 2026-08-18.

SEC EDGAR1 min

BOBULSKY SUSAN sold $32K of ADPT

The 30-second read

Why it matters

Market read

What to watch

Background

Ticker impact

Market effects

Counterpoint

Key entities

Full insider trading history

Related articles

ADPT Initiates Coverage On Goldman Sachs -- Rating Set to Buy

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

BTIG maintains Buy rating on Adaptive Biotechnologies, $34 price target

BTIG raises Adeptus Biotechnologies price target to $34 on guidelines

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

ROBINS CHAD M sold $14.9M of ADPT